Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Open Access
- 1 February 2015
- journal article
- research article
- Published by Elsevier BV in Cell
- Vol. 160 (5), 977-989
- https://doi.org/10.1016/j.cell.2015.01.042
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Proapoptotic BH3-Only BCL-2 Family Protein BIM Connects Death Signaling from Epidermal Growth Factor Receptor Inhibition to the MitochondrionCancer Research, 2007
- BH3 Profiling Identifies Three Distinct Classes of Apoptotic Blocks to Predict Response to ABT-737 and Conventional Chemotherapeutic AgentsCancer Cell, 2007
- Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyondStatistics in Medicine, 2007
- Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family membersCancer Cell, 2006
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeuticsCancer Cell, 2002
- Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and DeathScience, 2001
- Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal TumorThe New England Journal of Medicine, 2001
- Chronic Myeloid LeukemiaThe New England Journal of Medicine, 1999
- The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of ApoptosisScience, 1997